12-Month clinical outcomes of amphilimus drug eluting stents in an all-comers South-East Asian registry.

Autor:	Ho HH; Tan Tock Seng Hospital, Singapore., Sinaga DA; Awal Bros Hospital, Pekanbaru, Indonesia., Arshad MKM; Faculty of Medicine, Universiti Teknologi MARA, Selangor, Malaysia., Kasim S; Faculty of Medicine, Universiti Teknologi MARA, Selangor, Malaysia., Lee JH; Tan Tock Seng Hospital, Singapore., Khoo DZL; Tan Tock Seng Hospital, Singapore., Loh KK; Tan Tock Seng Hospital, Singapore., Jafary FH; Tan Tock Seng Hospital, Singapore., Ong PJL; Tan Tock Seng Hospital, Singapore., Lo SSS; Gleneagles Medical Centre, Penang, Malaysia.
Jazyk:	angličtina
Zdroj:	International journal of cardiology. Heart & vasculature [Int J Cardiol Heart Vasc] 2020 Jan 23; Vol. 26, pp. 100469. Date of Electronic Publication: 2020 Jan 23 (Print Publication: 2020).
DOI:	10.1016/j.ijcha.2020.100469
Abstrakt:	Background: Amphilimus-eluting stent (AES) is a novel polymer-free drug eluting stent that combines sirolimus with fatty acid as antiproliferative drug and has shown promising results in percutaneous coronary intervention.We evaluated the clinical safety and efficacy of AES in an all-comers South-East Asian registry. Methods: Between May 2014 to April 2017, 268 patients (88% male, mean age 60.1 ± 10.8 years) with 291 coronary lesions were treated with AES. The primary endpoint was major adverse cardiac events (MACE) ie a composite of cardiovascular mortality, myocardial infarction (MI) and target lesion revascularization (TLR) at 12-month follow-up. Results: The majority of patients presented with acute coronary syndrome (75%) and 75% had multi-vessel disease on angiography. Diabetes mellitus was present in 123 patients (46%). The most common target vessel for PCI was left anterior descending artery (43%) followed by right coronary artery (36%), left circumflex (10%) and left main (6%).The majority of lesions were type B-C (85%) by ACC/AHA lesion classification. An average of 1.25 ± 0.5 AES were used per patient, with mean AES diameter of 3.1 ± 0.4 mm and average total length of 34.8 ± 19.4 mm.At 12-month follow-up, 4% of patients developed MACE. MACE was mainly driven by cardiovascular mortality (1.5%), MI (2%) and TLR (1.5%). The rate of stent thrombosis was 1.5%. Conclusion: In a contemporary all-comers South-East Asian registry with high rate of diabetes mellitus, AES was found to be efficacious with a low incidence of MACE observed at 12-month follow-up. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2020 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu